Related Experiment Videos
Multiple myeloma: a case of a cure?
J L Robert1, N Tubiana, C Lejeune
1Institut J Paoli-I Calmettes, Marseille, France.
Nouvelle Revue Francaise D'Hematologie
|January 1, 1989
Summary
A rare cure was achieved in a patient with advanced multiple myeloma (IgA K, stage III). This case highlights long-term remission and potential cure after Melphalan-Prednisone treatment.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Multiple myeloma is a plasma cell malignancy with limited curative potential.
- Stage III IgA K multiple myeloma represents an advanced form of the disease.
- Long-term remission and cure are exceptionally rare in multiple myeloma.
Observation:
- A 54-year-old male diagnosed with stage III, IgA K multiple myeloma.
- The patient received 4 years of Melphalan-Prednisone treatment.
- Complete remission was observed 12 years post-diagnosis.
Findings:
- The patient met the criteria for cure 8 years after treatment cessation.
- Criteria included no measurable myeloma protein and normal bone marrow.
- Disappearance of osteolytic lesions was also noted.
Implications:
- This case suggests that cure may be achievable in select multiple myeloma patients.
- Long-term follow-up is crucial for defining cure in multiple myeloma.
- Further research into curative strategies for multiple myeloma is warranted.